Indaptus Therapeutics Announces Private Placement Of 20,338,974 Shares For Gross Proceeds Of ~$24M

The Company currently intends to use the net proceeds from the Private Placement for working capital, research and development and other general corporate purposes, which may include early-stage research and preclinical evaluation of a potential neurotechnology and neural-network-based device for certain sleep-related conditions, with a view toward a potential future FDA submission.